The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway

The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway

The diabetes medication canagliflozin (Cana) is a sodium glucose cotransporter 2 (SGLT2) inhibitor acting by increasing urinary glucose excretion and thus reducing hyperglycaemia. Cana treatment also reduces body weight. However, it remains unclear whether Cana could directly work on adipose tissue....

Full description

Bibliographic Details
Main Authors: Xuping Yang, Qinhui Liu, Yanping Li, Qin Tang, Tong Wu, Lei Chen, Shiyun Pu, Yingnan Zhao, Guorong Zhang, Cuiyuan Huang, Jinhang Zhang, Zijing Zhang, Ya Huang, Min Zou, Xiongjie Shi, Wei Jiang, Rui Wang, Jinhan He
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Adipocyte
Subjects:
canagliflozin
adipocytes
mitochondrial biogenesis
energy homoeostasis
pgc-1α
Online Access:http://dx.doi.org/10.1080/21623945.2020.1807850

Internet

http://dx.doi.org/10.1080/21623945.2020.1807850

Similar Items